首页|期刊导航|Cancer Innovation|Rationale and Trial Design of DAWNA-FES Trial:Single-Arm Phase Ⅱ Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on[^(18)F]FES PET/CT in Patients With HR+/HER2−Advanced Breast Cancer

Rationale and Trial Design of DAWNA-FES Trial:Single-Arm Phase Ⅱ Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on[^(18)F]FES PET/CT in Patients With HR+/HER2−Advanced Breast CancerOA

中文摘要

Background:Cyclin-dependent kinase 4/6(CDK4/6)inhibitors have become a cornerstone in the first-line management of hormone receptor-positive,human epidermal growth factor receptor 2-negative(HR+/HER2−)advanced breast cancer.Despite their clinical efficacy,most patients eventually experience disease progression,and optimal treatment strategies following CDK4/6 inhibitor resistance remain unclear.Emerging evidence suggests that switching endocrine therapy(ET)while continuing cyclin inhibition may provide additional clinical benefit.Dalpiciclib,a selective CDK4/6 inhibitor,in combination with physician-selected ET,represents a potential option in this setting.Concurrently,16α-[^(18)F]fluoro-17β-estradiol([^(18)F]FES)PET/CT,a novel imaging modality targeting estrogen receptors(ER),enables non-invasive,whole-body assessment of ER expression in metastatic lesions,offering a personalized approach to treatment selection.Methods:This is a prospective,single-center,single-arm Phase Ⅱ clinical trial evaluating the efficacy and safety of dalpiciclib plus ET in HR+/HER2−advanced breast cancer patients who progressed on prior CDK4/6 inhibitor therapy.Forty eligible patients with confirmed metastases and at least one[^(18)F]FES-positive lesion will be enrolled.Participants will receive dalpiciclib combined with ET as determined by the treating physician.The primary endpoint is progression-free survival(PFS).Secondary endpoints include objective response rate(ORR),disease control rate(DCR),and overall survival(OS).Discussion:Beyond evaluating efficacy,this single-center phase Ⅱ trial will provide practical insight into the feasibility of[^(18)F]FES PET/CT-guided patient selection,including standardized imaging workflows and multidisciplinary implementation in routine clinical research.Positive outcomes may support a personalized,imaging-guided strategy to prolong disease control after prior CDK4/6 inhibitor progression.

Ru Yao;Yang Qu;Zhixin Hao;Ying Xu;Jiahui Zhang;Jie Lian;Lu Gao;Songjie Shen;Feng Mao;Bo Pan;Qiang Sun;Li Huo;Yidong Zhou

Department of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Breast Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China

医药卫生

16α-[^(18)F]fluoro-17β-estradiolCDK4/6 inhibitorestrogen receptormetastatic breast cancertreatment response

《Cancer Innovation》 2026 (3)

P.1-8,8

General Program of National Natural Science Foundation of China,Grant/Award Number:82573669National High Level Hospital Clinical Research Funding,Grant/Award Number:2025-PUMCH-A-147Project for post-marketing clinical research of innovative drugs by Medical and Health Science and Technology Development Research Center of the National Health Commission,Grant/Award Number:WKZX2024CX103104。

10.1002/cai2.70058

评论